DeepMed Research

Bausch & Lomb Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1992-10-08

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of B + L Ophthalmic Viscosurgical Device (OVD) CVisc50

Not Applicable

Completed

Conditions: Cataract

Interventions: Device: CVisc50 OVD
Device: ProVisc OVD
Procedure: Cataract Surgery

First Posted Date: 2019-12-10

Last Posted Date: 2024-05-28

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 390

Registration Number: NCT04192630

Locations: 🇺🇸
Bausch Site 011, Newport Beach, California, United States
🇺🇸
Bausch Site 004, Torrance, California, United States
🇺🇸
Bausch Site 014, Goodlettsville, Tennessee, United States

and more 19 locations

A Safety and Effectiveness Study of a New Preservative Free Rewetting Drop

Not Applicable

Completed

Conditions: Contact Lens Wear

Interventions: Device: BL-300-PFM04
Device: OPTI-FREE

First Posted Date: 2019-11-25

Last Posted Date: 2024-07-10

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 369

Registration Number: NCT04175340

Locations: 🇺🇸
Bausch Site 104, Decatur, Georgia, United States
🇺🇸
Bausch Site 108, San Francisco, California, United States
🇺🇸
Bausch Site 106, Sarasota, Florida, United States

and more 12 locations

A Study to Evaluate the Safety and Efficacy of Kalifilcon A Daily Disposable Contact Lens

Not Applicable

Completed

Conditions: Contact Lens Wear

Interventions: Device: Kalifilcon A Daily Disposable Contact Lenses
Device: Biotrue ONEday Daily Disposable Contact Lenses

First Posted Date: 2019-11-08

Last Posted Date: 2020-11-19

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 252

Registration Number: NCT04158466

Locations: 🇺🇸
Bausch Site 16, Honolulu, Hawaii, United States
🇺🇸
Bausch Site 1, Saint Louis, Missouri, United States
🇺🇸
Bausch Site 11, Bloomington, Minnesota, United States

and more 13 locations

Safety and IOP-Lowering Effects of WB007

Phase 1

Completed

Conditions: Ocular Hypertension
Glaucoma, Primary Open Angle

Interventions: Drug: Timolol 0.5%
Drug: WB007 0.05%
Drug: WB007 0.15%
Drug: WB007 0.4%

First Posted Date: 2019-11-04

Last Posted Date: 2025-03-27

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 77

Registration Number: NCT04149899

Locations: 🇺🇸
Eye Research Foundation, Newport Beach, California, United States

Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

Phase 3

Completed

Conditions: Dry Eye Disease (DED)

Interventions: Drug: NOV03
Drug: Placebo

First Posted Date: 2019-10-25

Last Posted Date: 2024-10-23

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 599

Registration Number: NCT04139798

Locations: 🇺🇸
Bausch Site 112, Indianapolis, Indiana, United States
🇺🇸
103, Torrance, California, United States
🇺🇸
Bausch Site 115, Jacksonville, Florida, United States

and more 26 locations

Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)

Phase 3

Completed

Conditions: Dry Eye Disease (DED)

Interventions: Drug: NOV03

First Posted Date: 2019-10-25

Last Posted Date: 2024-03-04

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 256

Registration Number: NCT04140227

Locations: 🇺🇸
Bausch Site 101, Newport Beach, California, United States
🇺🇸
Bausch Site 123, Torrance, California, United States
🇺🇸
Bausch Site 103, Torrance, California, United States

and more 25 locations

A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension

Phase 4

Withdrawn

Conditions: Ocular Hypertension

Interventions: Drug: Latanoprostene Bunod
Drug: Placebo

First Posted Date: 2019-10-25

Last Posted Date: 2024-03-04

Lead Sponsor: Bausch & Lomb Incorporated

Registration Number: NCT04140279

Locations: 🇺🇸
Bausch Site 001, Rochester, Minnesota, United States

A Study With Technolas® TENEO 317 Model 2 Excimer Laser to Treat Participants With Myopia or Myopic Astigmatism

Not Applicable

Completed

Conditions: Myopic Astigmatism
Myopia

Interventions: Device: Technolas® TENEO 317 Model 2

First Posted Date: 2019-10-01

Last Posted Date: 2024-06-14

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 168

Registration Number: NCT04111757

Locations: 🇺🇸
Bausch Site 108, Omaha, Nebraska, United States
🇺🇸
Bausch Site 109, Sioux Falls, South Dakota, United States
🇺🇸
Bausch Site 106, Portsmouth, New Hampshire, United States

and more 7 locations

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

Phase 1

Completed

Conditions: Glaucoma
Open Angle or Ocular Hypertension

Interventions: Drug: brinzolamide 1% ophthalmic suspension
Drug: Azopt 1%

First Posted Date: 2019-04-01

Last Posted Date: 2023-05-09

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 637

Registration Number: NCT03896633

Locations: 🇺🇸
Various, Bridgewater, New Jersey, United States

A Safety and Effectiveness Study of BL-ABT12 Multi-Purpose Solution for Use by Participants With Soft Contact Lenses

Not Applicable

Completed

Conditions: Contact Lens Wear

Interventions: Device: ABT12 Multi-Purpose Solution
Device: COMPLETE Multi-Purpose Solution
Device: Sensitive Eyes® Rewetting Drops

First Posted Date: 2019-04-01

Last Posted Date: 2023-03-03

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 252

Registration Number: NCT03897751

Locations: 🇺🇸
Bausch Site 14, Vestal, New York, United States
🇺🇸
Bausch Site 17, Brentwood, Tennessee, United States
🇺🇸
Bausch Site 2, San Diego, California, United States

and more 14 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy